Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry

Cancer

Volumn 121, Issue 17, 2015, Pages 3036-3045

  Lu, Yusheng ^a   Liang, Haiyan ^a   Yu, Ting ^a   Xie, Jingjing ^a   Chen, Shuming ^b   Dong, Haiyan ^a   Sinko, Patrick J ^c   Lian, Shu ^a   Xu, Jianguo ^a   Wang, Jichuang ^a   Yu, Suhong ^a   Shao, Jingwei ^a   Yuan, Bo ^b   Wang, Lie ^b   Jia, Lee ^a  

^a FUZHOU UNIVERSITY   (China)

^b FUZHOU GENERAL HOSPITAL   (China)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

circulating tumor cell reculturing; circulating tumor cells; colorectal carcinoma; fluorescence activated cell sorting; immunomagnetic negative enrichment

Indexed keywords

CD47 ANTIGEN; CYTOKERATIN 1; CYTOKERATIN 10; CYTOKERATIN 14; CYTOKERATIN 15; CYTOKERATIN 16; CYTOKERATIN 19; CYTOKERATIN 2; CYTOKERATIN 3; CYTOKERATIN 4; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; HERMES ANTIGEN; CD44 PROTEIN, HUMAN; CD47 PROTEIN, HUMAN;

ARTICLE; BLOOD SAMPLING; CACO 2 CELL LINE; CANCER GROWTH; CANCER STAGING; CELL COUNT; CELL ISOLATION; CELL VIABILITY; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COLORECTAL CANCER CELL LINE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HCT116 CELL LINE; HT29 CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOMAGNETIC NEGATIVE ENRICHMENT; LOVO CELL LINE; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; PROTEIN EXPRESSION; QUANTITATIVE STUDY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STAINING; SW480 CELL LINE; TUMOR VOLUME; COLORECTAL TUMOR; IMMUNOMAGNETIC SEPARATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR EMBOLISM;

ANTIGENS, CD44; ANTIGENS, CD47; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FLOW CYTOMETRY; HUMANS; IMMUNOMAGNETIC SEPARATION; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; SENSITIVITY AND SPECIFICITY;

EID: 84939563058     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29444     Document Type: Article

References (46)

1. Yu M, Stott S, Toner M, Maheswaran S, Haber DA,. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011; 192: 373-382.
2. Chaffer CL, Weinberg RA,. A perspective on cancer cell metastasis. Science. 2011; 331: 1559-1564.
3. Nguyen DX, Bos PD, Massague J,. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009; 9: 274-284.
4. Sethi N, Kang Y,. Unravelling the complexity of metastasis-molecular understanding and targeted therapies. Nat Rev Cancer. 2011; 11: 735-748.
5. Kim MY, Oskarsson T, Acharyya S, et al., Tumor self-seeding by circulating cancer cells. Cell. 2009; 139: 1315-1326.
6. Plaks V, Koopman CD, Werb Z,. Cancer. Circulating tumor cells. Science. 2013; 341: 1186-1188.
7. Wang J, Chen J, Wan L, et al., Synthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486). AAPS J. 2014; 16: 289-298.
8. Yu M, Bardia A, Aceto N, et al., Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014; 345: 216-220.
9. Pantel K, Alix-Panabieres C, Riethdorf S,. Cancer micrometastases. Nat Rev Clin Oncol. 2009; 6: 339-351.
10. Vona G, Sabile A, Louha M, et al., Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol. 2000; 156: 57-63.
11. Pantel K, Cote RJ, Fodstad O,. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999; 91: 1113-1124.
12. Xenidis N, Perraki M, Kafousi M, et al., Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol. 2006; 24: 3756-3762.
13. Nagrath S, Sequist LV, Maheswaran S, et al., Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007; 450: 1235-1239.
14. Kling J,. Beyond counting tumor cells. Nat Biotechnol. 2012; 30: 578-580.
15. Riethmuller G, Holz E, Schlimok G, et al., Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 1998; 16: 1788-1794.
16. Went PT, Lugli A, Meier S, et al., Frequent EpCAM protein expression in human carcinomas. Hum Pathol. 2004; 35: 122-128.
17. Xie J, Zhao R, Gu S, et al., The architecture and biological function of dual antibody-coated dendrimers: enhanced control of circulating tumor cells and their hetero-adhesion to endothelial cells for metastasis prevention. Theranostics. 2014; 4: 1250-1263.
18. Baeuerle PA, Gires O,. EpCAM (CD326) finding its role in cancer. Br J Cancer. 2007; 96: 417-423.
19. Thierry B, Kurkuri M, Shi JY, Lwin LE, Palms D,. Herceptin functionalized microfluidic polydimethylsiloxane devices for the capture of human epidermal growth factor receptor 2 positive circulating breast cancer cells. Biomicrofluidics. 2010; 4: 32205.
20. Stott SL, Lee RJ, Nagrath S, et al., Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010; 2: 25ra23.
21. Maheswaran S, Sequist LV, Nagrath S, et al., Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359: 366-377.
22. Balasubramanian S, Kagan D, Hu CM, et al., Micromachine-enabled capture and isolation of cancer cells in complex media. Angew Chem Int Ed Engl. 2011; 50: 4161-4164.
23. Riethdorf S, Fritsche H, Muller V, et al., Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13: 920-928.
24. Miller MC, Doyle GV, Terstappen LW,. Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010; 2010: 617421.
25. Lu Y, Yu T, Liang H, et al., Nitric oxide inhibits hetero-adhesion of cancer cells to endothelial cells: restraining circulating tumor cells from initiating metastatic cascade. Sci Rep. 2014; 4: 4344.
26. Munz M, Baeuerle PA, Gires O,. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009; 69: 5627-5629.
27. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC,. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol. 2007; 171: 386-395.
28. Allard WJ, Matera J, Miller MC, et al., Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10: 6897-6904.
29. Wittekind C, Bertolini J,. TNM system 2010 amendments in the new 7th edition of the TNM classification of malignant tumours. Onkologe. 2010; 16: 175-180.
30. Frisch SM, Francis H,. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994; 124: 619-626.
31. Kishihara K, Penninger J, Wallace VA, et al., Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice. Cell. 1993; 74: 143-156.
32. Trowbridge IS, Thomas ML,. CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol. 1994; 12: 85-116.
33. Baccelli I, Schneeweiss A, Riethdorf S, et al., Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013; 31: 539-544.
34. Jaiswal S, Jamieson CH, Pang WW, et al., CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009; 138: 271-285.
35. Jaiswal S, Chao MP, Majeti R, Weissman IL,. Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 2010; 31: 212-219.
36. Gardai SJ, McPhillips KA, Frasch SC, et al., Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005; 123: 321-334.
37. Willingham SB, Volkmer JP, Gentles AJ, et al., The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012; 109: 6662-6667.
38. Chao MP, Weissman IL, Majeti R,. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012; 24: 225-232.
39. Tseng D, Volkmer JP, Willingham SB, et al., Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A. 2013; 110: 11103-11108.
40. Marhaba R, Zoller M,. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004; 35: 211-231.
41. Nagano O, Saya H,. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004; 95: 930-935.
42. Liu C, Kelnar K, Liu B, et al., The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17: 211-215.
43. Kantara C, O'Connell MR, Luthra G, et al., Methods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse/metastasis. Lab Invest. 2015; 95: 100-112.
44. Cayrefourcq L, Mazard T, Joosse S, et al., Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res. 2015; 75: 892-901.
45. Zhang L, Ridgway LD, Wetzel MD, et al., The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 2013; 5: 180ra148.
46. Sheng W, Ogunwobi OO, Chen T, et al., Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Lab Chip. 2014; 14: 89-98.